Japan, Feb. 27 -- REGENERON PHARMACEUTICALS INC has got intellectual property rights for 'ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF.' Other related details are as follows:
Application Number: JP,2024-091536
Category (FI): A61P31/04,C07K16/28,C12N15/13,A61K47/68,A61K47/40,A61K47/22,A61K47/42,A61K39/395@N,A61P3/06,A61P9/10,A61P13/02,105,A61P17/00,101,A61P19/02,A61P29/00,A61P43/00,111,A61P27/02,A61P3/00
Stage: PROBLEM TO BE SOLVED: To provide antibodies or antigen binding fragments that bind to MSR1 and methods of use thereof.SOLUTION: Provided is an antibody that bind to human MSR1 with a high affinity. In an embodiment, the antibody binds to MSR1 without blocking the binding of modified LDL to MSR1 or blocking the binding less than 90%. In some embodiments, the antibody binds to MSR1 expressed on the cell surface and is internalized. The antibody of the invention may be a fully human antibody. The invention includes an anti-MSR1 antibody or antigen binding fragment thereof conjugated to a drug or therapeutic compound.SELECTED DRAWING: Figure 21 (Grant)
Filing Date: June 5, 2024
Publication Date: Oct. 2, 2024
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication.
